FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia By Ogkologos - December 3, 2024 972 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR New on NCI’s Websites for September 2023 September 29, 2023 Workout Wednesday – Leg Stretches Part 2 July 15, 2020 EMA Recommends Granting a Marketing Authorisation for Biosimilar Bevacizumab June 30, 2020 Man Who Lost His Mother to Breast Cancer Opens Resource Center... May 6, 2021 Load more HOT NEWS Professor Ian Tomlinson: “Philanthropy is priceless to science” What to Do If You’ve Been Diagnosed With Cancer in the... EMA Recommends Granting a Marketing Authorisation for Relacorilant Olivia Newton-John Talks About Her Use Of Medical Cannabis During Cancer...
